compani updat chang price
indic readi rais guidanc end market strength persist
see greater expect academ strength eu
higher revenu pull-through quarter lunar new year
thesi updat first apolog ron burgundi moment
first take question mark suppos heart clearli
publish system didnt love agil much say everyth
fire cylind probabl understat doubl digit
growth proper outcom consid peer print
confirm view still superior growth asset complex
right ex margin perform also continu solid ex
dgg havent even seen key new product truli kick
furthermor guidanc remain readili achiev move
high end ep sorri didier hold back model
feel like tri rein prize racehors final stretch
key race addit key punchlin see
manag open potenti tap balanc sheet right
transact add new element ep upsid pictur albeit
would reiter one need contempl order
remain construct all-in see share nice tomorrow given
momentum end market b/ option keep outperform
rais pt yet
capit deploy prioriti remain capital-expenditure though
open larger acquisit line long term strategi
 saw revenu backlog mostli
ship
 still think pharma msd growth
 strength biopharma small molecul side pharma
 strength gener market
 strong high-margin growth patholog dx busi
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
assum core growth chemic energi
stronger forecast growth academ govern
 robust eu china
 back offic oper handl incom custom order
 insourc logist tn
outlin potenti impact larger-scal pharma
 would see paus new instrument purchas new opportun acg busi relat enterpris servic
 consolid vendor would also favor agil
 believ complet end
 see revenu
million except per share data fy end decemb scienc appli market organ genom organ cross organ measurementtot organ gp less total scienc appli market genom cross op less ep share inc net inc price-to-earnings prem disc februari
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
laboratori corp america hold
articl articl
time dissemin februari et
analyst ross muken vijay kumar luke sergott primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view research
